The characteristics of Japanese guidelines on diagnosis and treatment of cardiac sarcoidosis compared with the previous guidelines New guidelines on cardiac sarcoidosis in Japan

Main Article Content

Fumio Terasaki
Kengo Kusano
Takatomo Nakajima
Yoshikazu Yazaki
Shin-ichiro Morimoto
Daniel A. Culver
Mitsuaki Isobe


Guidelines, Diagnosis, Isolated cardiac sarcoidosis


Sarcoidosis in Japanese sarcoidosis is characterized by a high prevalence of cardiac involvement. In this regard, cardiac sarcoidosis (CS) continues to be an important focus of study among physicians caring for sarcoidosis in Japan. The Japanese Ministry of Health, Labor and Welfare (MHLW) and Japan Society of Sarcoidosis and other Granulomatous Disorders (JSSOG) have published clinical guidelines aiming to assist clinical practices. Recently, the Japanese Circulation Society (JCS) has published new clinical guidelines for the diagnosis and treatment of CS that contain several new insights compared to previously published guidelines in Japan and other countries.

Abstract 599 | PDF Downloads 526


1) The Japan Society of Sarcoidosis and Other Granulomatous Disorders, the Diffuse Pulmonary Study Group of the Health and Labor Sciences Research Grant-supported Rare/Intractable Disease Project, et al. Committee for revision of the diagnostic standard for sarcoidosis. Diagnostic standard and guideline for sarcoidosis - 2006. The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders 2007; 27: 89-102. [In Japanese]
2) JCS Joint Working Group. Guidelines for diagnosis and treatment of myocarditis (JCS 2009): Digest version. Circ J 2011; 75: 734-743.
3) Judson MA, Costabel U, Drent M, et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 19-27.
4) Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11: 1305-1323.
5) Terasaki F, Azuma A, Anzai T, et al; Japanese Circulation Society Joint Working Group. JCS 2016 Guideline on diagnosis and treatment of cardiac sarcoidosis - Digest version. Circ J 2019; 83: 2329-2388. [Epub ahead of print]
6) Terasaki F, Yoshinaga K. New guidelines for diagnosis of cardiac sarcoidosis in Japan. Ann Nucl Cardiol 2017; 3: 42-45.
7) Isobe M, Tezuka D. Isolated cardiac sarcoidosis: clinical characteristics, diagnosis and treatment. Int J Cardiol 2015; 182: 132-140.
8) Kumita S, Yoshinaga K, Miyagawa M, et al; Committee for diagnosis of cardiac sarcoidosis using 18F-FDG PET, Japanese Society of Nuclear Cardiology. Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations. J Nucl Cardiol 2019; 26: 1414-1433.
9) Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63: 329-336.
10) Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol 2017; 24: 1741-1758.
11) Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015; 131: 624-632.
12) Aravena C, Almeida FA, Culver DA, et al. The utility of endobronchial ultrasound-transbronchial needle aspiration in patients with suspected extra-pulmonary sarcoidosis without thoracic lymphadenopathy Respir Med 2020 Sep;171. Epub 2020 Jul 7.
13) Kawai H, Sarai M, Kato Y, et al. Diagnosis of isolated cardiac sarcoidosis based on new guidelines. ESC Heart Fail. 2020; 7: 2662-2671.
14) The Japanese Society of Sarcoidosis and Other Granulomatous Disorders, the Japanese Respiratory Society, the Japanese College of Cardiology, et al. Sarcoidosis Treatment Guideline Preparation Committee. The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders 23: 105-114, 2003. [in Japanese]
15) Yazaki Y, Isobe M, Hiroe M, et al: Prognostic determinants of long-term survival in Japanese patient with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88: 1006-1010.
16) Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol 2016; 68:411-421.
17) Nagai T, Nagano N, Sugano Y, et al. Effect of discontinuation of prednisolone therapy on risk of cardiac mortality associated with worsening left ventricular dysfunction in cardiac sarcoidosis. Am J Cardiol 2016;117: 966-971.
18) Fujita S, Terasaki F, Miyamura M, et al. A patient with cardiac sarcoidosis in whom an abnormal myocardial uptake of fluorine-18 fluorodeoxyglucose and sustained ventricular tachycardia recurred 3.5 years after discontinuing oral corticosteroid therapy. Intern Med 2020; 59: 2275-2280.
19) Segawa M, Fukuda K, Nakano M, et al. Time course and factors correlating with ventricular tachyarrhythmias after introduction of steroid therapy in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2016; 9. pii: e003353.
20) Nagai S, Yokomatsu T, Tanizawa K, et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med 2014; 53: 427-433.
21) Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009; 157: 9-21.
22) Kumar S, Barbhaiya C, Nagashima K, et al. Ventricular tachycardia in cardiac sarcoidosis: Characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol 2015; 8: 87-93.
23) Bandyopahyay D, Sahoo D, Zein J, et al. Outcome of cardiac sarcoidosis after radiofrequency ablation and placement of AICD- A propensity matched analysis. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32: 70-79.
24) Kouranos V, Tzelepis GE, Rapti A, et al. Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis. JACC Cardiovasc Imaging 2017;10:1437-1447.
25) Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53: 241-248.
26) Yoshinaga K, Tamaki N. Current status of nuclear cardiology in Japan: Ongoing efforts to improve clinical standards and to establish evidence. J Nucl Cardiol 2015; 22: 690-699.
27) Ishida Y, Yoshinaga K, Miyagawa M, et al. Recommendations for (18)F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Med 2014; 28: 393-403.
28) Kumita S, Yoshinaga K, Miyagawa M, et al. Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis—2018 update: Japanese Society of Nuclear Cardiology Recommendations. Ann Nucl Cardiol 2019; 5: 141–159.
29) Ribeiro Neto ML, Jellis CL, Joyce E, et al. Update in cardiac sarcoidosis. Ann Am Thorac Soc 2019;16 :1341-1350.
30) Simonen P, Lehtonen J, Kandolin R, et al. F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis. Am J Cardiol 2015; 116: 1581-1585.
31) Otsuka K, Terasaki F, Eishi Y, et al. Cardiac sarcoidosis underlies idiopathic dilated cardiomyopathy – importance of mediastinal lymphadenopathy in differential diagnosis. Circ J 2007; 71: 1937-1941.
32) Ribeiro Neto ML, Jellis C, Hachamovitch R, et al. Performance of diagnostic criteria in patients clinically judged to have cardiac sarcoidosis: Is it time to regroup? Am Heart J 2020; 223:106-109.
33) Lawal I, Sathekge M. F-18 FDG PET/CT imaging of cardiac and vascular inflammation and infection. Br Med Bull 2016; 120: 55-74.
34) Millar BC, de Camargo RA, Alavi A, Moore JE. PET/Computed tomography evaluation of infection of the heart. PET Clin 2019; 14: 251-269.
35) Chen W, Jeudy J. Assessment of myocarditis: cardiac MR, PET/CT, or PET/MR? Curr Cardiol Rep 2019; 21: 76.
36) Protonotarios A, Wicks E, Ashworth M, et al. Prevalence of 18F-fluorodeoxyglucose positron emission tomography abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol 2019; 284: 99-104.
37) Aoyama R, Takano H, Kobayashi Y, et al. Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy using 18F-fluorodeoxyglucose positron emission tomography. PLoS One 2017; 12: e0188479.
38) Norikane T, Yamamoto Y, Takami Y, et al. Occasionally increased 18F-FDG uptake in apical hypertrophic cardiomyopathy on serial follow-up PET/CT. J Nucl Cardiol 2019; 26: 2125-2128.
39) Christensen TE, Bang LE, Holmvang L, et al. Cardiac 99mTc sestamibi SPECT and 18F FDG PET as viability markers in Takotsubo cardiomyopathy. Int J Cardiovasc Imaging 2014; 30: 1407-1416.
40) Egashira T, Makino S, Kunitomi A, et al. Necessity for rule out coronary artery disease with the positive findings of 18F-FDG-PET in case of systemic sarcoidosis. Int J Cardiol 2014; 172: e401-402.